Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TEVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTeva announces acquisition of Emalex Biosciences and reports Q1 2026 earnings
Filed April 29, 2026 · Period ending April 29, 2026 · ~1 min read
Key Changes
-
high
Teva entered into a definitive agreement to acquire Emalex Biosciences, a deal announced April 29, 2026. Financial terms and strategic rationale were not disclosed in the 8-K filing itself.
Item 8.01 view on EDGAR → -
high
Teva reported first quarter 2026 financial results via press release on April 29, 2026. The 8-K references the earnings report as an exhibit but does not include actual financial figures or performance metrics.
Item 2.02 verify on EDGAR →
Summary
Teva Pharmaceutical disclosed two significant corporate events on April 29, 2026: the company reported its first quarter 2026 financial results and announced a definitive agreement to acquire Emalex Biosciences. The acquisition represents a strategic expansion for Teva, though the 8-K filing does not provide deal terms, purchase price, or expected closing timeline. Retail investors should note that while both events are material, the 8-K itself is a notification filing that references press releases as exhibits rather than providing detailed information.
The actual financial performance metrics for Q1 2026 and the strategic rationale for the Emalex acquisition are contained in separate press releases. Investors should review the referenced press releases (Exhibits 99.1 and 99.2) for complete details on quarterly performance and acquisition terms. Watch for subsequent filings that may disclose deal financing, regulatory approvals needed, and integration plans for Emalex.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 29, 2026, Teva Pharmaceutical Industries Ltd. (the “Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.
Teva disclosed its first quarter 2026 financial results through a press release dated April 29, 2026. The 8-K references the press release as Exhibit 99.1 but does not include the actual financial figures or performance metrics in the body of the filing itself.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
on April 29, 2026, the Company issued a press release announcing that it has entered into a definitive agreement to acquire Emalex Biosciences.
Teva Pharmaceutical has entered into a binding agreement to acquire Emalex Biosciences, a transaction disclosed via press release on April 29, 2026. The 8-K does not provide financial terms, strategic rationale, or closing timeline, but confirms the deal is definitive.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Teva to Acquire Emalex Biosciences
Teva announced an acquisition of Emalex Biosciences. The 8-K references an exhibit with details about this transaction, but the terms, purchase price, and strategic rationale are not included in this filing body.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify